ClinicalTrials.gg
RecruitingNCT06985784Updated Nov 10, 2026

Virtual Reality Interventions for the Improvement of Depression, Anxiety and Pain in Patients With Head and Neck Cancer and Caregivers

An interventional study of Interview and Medical Device Usage and Evaluation in Head and Neck Carcinoma, sponsored by City of Hope Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by City of Hope Medical Center · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This clinical trial tests how well a three-dimensional (3D) mindfulness virtual reality (VR) versus (vs) two-dimensional (2D) non-immersive interventions works in improving depression, anxiety, pain, and/or stress in patients with head and neck cancer (HNC) undergoing radiation or chemoradiation (C/RT), and their caregivers. HNC patients undergoing C/RT can experience higher levels of depression, anxiety, distress and pain that negatively impact their quality of life. VR allows for a realistic experience and works as an effective distraction tool from the state of pain or anxiety without use of drugs and with minimal associated risk to patients. VR has been shown to help reduce symptoms of depression, anxiety and pain in non-cancer patients, however there is limited evidence of how well VR use works in cancer patients, especially in patients undergoing C/RT for HNC. Caregivers of these patients also experience high levels of anxiety and distress. Using VR interventions may improve depression, anxiety, pain and/or stress in patients with HNC undergoing C/RT and their caregivers.

Read the detailed description

PRIMARY OBJECTIVE:

I. Feasibility and acceptability of 3D mindfulness VR- vs 2D in HNC patients undergoing C/RT.

SECONDARY OBJECTIVES:

I. Assess patient- and caregiver-preference for 3D VR and non-immersive interventions.

II. Preliminary efficacy in reduction in depressive symptoms, anxiety and pain.

OUTLINE: Participants are assigned to 1 of 2 arms.

ARM A: Participants receive 3D mindfulness VR headset consisting of 6 resilience skills training sessions over 30 minutes three times a week (TIW) for 6-7 weeks then weekly for 4 weeks. Participants also wear a Fitbit activity tracker to monitor heart rate, sleep and activity throughout the study.

ARM B: Participants receive 2D non-immersive VR headset consisting of 2 scenarios - walk in the nature and beach TIW for 6-7 weeks then weekly for 4 weeks. Participants also wear a Fitbit activity tracker to monitor heart rate, sleep and activity throughout the study.

02

Conditions studied

  • Head and Neck Carcinoma
03

In context

Lead sponsor

City of Hope Medical Center is the lead sponsor of 677 studies on the registry; 181 are open to participants now.

Of its 31 completed or terminated interventional studies of FDA-regulated products, 12 (39%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PATIENTS: Documented of the participant and/or legally authorized representative

    • Assent, when appropriate, will be obtained per institutional guidelines
  • PATIENTS: ≥ 18 years
  • PATIENTS: Self-reported normal or corrected to normal vision and hearing
  • PATIENTS: Ambulatory (permitted to use walking aids such as cane or crutch)
  • PATIENTS: Ability to read and understand English for questionnaires
  • PATIENTS: Scheduled to undergo C/RT for their HNC
  • CAREGIVERS: Documented informed consent of the participant and/or legally authorized representative

    • Assent, when appropriate, will be obtained per institutional guidelines
  • CAREGIVERS: ≥ 18 years
  • CAREGIVERS: Self-reported normal or corrected to normal vision and hearing
  • CAREGIVERS: Ability to read and understand English for questionnaires
  • CAREGIVERS: A care giver identified by the patient and defined as a person who knows the patient well and is involved in the patient's medical care

Exclusion criteria

Exclusion Criteria:

  • PATIENTS: An employee who is under the direct/ indirect supervision of the principal investigator (PI)/ a co-investigator/ the study manager
  • PATIENTS: A direct study team member
  • PATIENTS: Inability to complete the surveys
  • PATIENTS: Serious mental illness
  • PATIENTS: Previous head and neck cancer treatment
  • PATIENTS: History of any psychiatric disease treatment with anti-depressants, substance abuse, post-traumatic stress disorder (PTSD), chronic pain (> 3 months)
  • PATIENTS: Cancer in or around the eyes or ears; visual, hearing or cognitive impairment
  • CAREGIVERS: An employee who is under the direct/ indirect supervision of the PI/ a co-investigator/ the study manager
  • CAREGIVERS: A direct study team member
  • CAREGIVERS: Inability to complete the surveys
  • CAREGIVERS: Serious mental illness
  • CAREGIVERS: History of any psychiatric disease treatment with anti-depressants, substance abuse, PTSD
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Arm A (3D mindfulness VR headset)

    Participants receive 3D mindfulness VR headset consisting of 6 resilience skills training sessions over 30 minutes TIW for 6-7 weeks then weekly for 4 weeks. Participants also wear a Fitbit activity tracker to monitor heart rate, sleep and activity throughout the study.

    Other: Interview · Other: Medical Device Usage and Evaluation · Other: Questionnaire Administration · Other: Virtual Technology Intervention

  • Active comparator
    Arm B (2D non-immersive VR headset)

    Participants receive 2D non-immersive VR headset consisting of 2 scenarios - walk in the nature and beach TIW for 6-7 weeks then weekly for 4 weeks. Participants also wear a Fitbit activity tracker to monitor heart rate, sleep and activity throughout the study.

    Other: Interview · Other: Medical Device Usage and Evaluation · Other: Questionnaire Administration · Other: Virtual Technology Intervention

Interventions

  • OtherInterview

    Ancillary studies

  • OtherMedical Device Usage and Evaluation

    Wear a Fitbit

  • OtherQuestionnaire Administration

    Ancillary studies

  • OtherVirtual Technology Intervention

    Receive 3D mindfulness VR headset

    Also known as: Virtual Reality Intervention, Virtual Technology

  • OtherVirtual Technology Intervention

    Receive 2D non-immersive VR headset

    Also known as: Virtual Reality Intervention, Virtual Technology

06

What researchers measure

Primary outcomes

  1. Recruitment rate (Feasibility)

    Will be considered feasible if ≥ 50% of patients agree to participate. Will be assessed using summary statistics.

    Time frame: Up to 11 weeks

  2. Retention rate (Feasibility)

    Will be considered feasible if ≥ 70% of patients are retained. Will be assessed using summary statistics.

    Time frame: Up to 11 weeks

  3. Adherence to three-dimensional (3D) mindfulness virtual reality (VR) intervention (Feasibility)

    Will be considered feasible if ≥ 50% of patients use the 3D mindfulness VR intervention. Will be assessed using summary statistics.

    Time frame: Up to 11 weeks

  4. Completion of electronic patient reported outcomes (ePRO) (Feasibility)

    Will be considered feasible if ≥ 70% ePRO assessments are completed. Will be assessed using summary statistics.

    Time frame: Up to 11 weeks

  5. Acceptability of 3D mindfulness VR intervention

    Will be considered acceptable if ≥ 50% patients have greater than neutral satisfaction at the end of the study period. Will be assessed using summary statistics.

    Time frame: Up to 11 weeks

Secondary outcomes

  1. Preferences for VR based interventions

    Will be assessed by interviews to obtain feedback. Descriptive statistics to summarize satisfaction questionnaire.

    Time frame: Up to 30 days after treatment completion

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Nov 2027, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2025
First posted
May 22, 2025
StartActual
Jun 25, 2025
Primary completionEst.
Nov 9, 2027
CompletionEst.
Nov 9, 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06985784
Responsible party
Sponsor
First posted
May 22, 2025
Start date
Jun 25, 2025
Primary completion
Nov 9, 2027 (estimated)
Completion
Nov 9, 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Krupal Patel
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion